Atmani F, Lacour B, Daudon M
University of Florida, Department of Pathology, College of Medicine, Gainesville, USA.
Nephrologie. 1996;17(3):157-62.
During about ten years, nephrocalcin was considered the main calcium oxalate crystal growth inhibitor. Today, it appears only a urinary protein inhibitor among other ones such as non polymerized Tamm-Horsfall protein, uropontin or crystal matrix protein (CMP), a protein derived from prothrombin. All these molecules are able to inhibit either crystal growth or aggregation of calcium oxalate in urine. Another protein, named renal lithostathine, was also reported to be a potent inhibitor of secondary nucleation and growth of calcium carbonate crystals. A new urinary inhibitor of calcium oxalate formation was isolated from the urine of healthy subjects using chromatographic procedures. It is a macromolecule with a molecular weight (MW) of approximately 35 kDa as estimated by polyacrylamide gel electrophoresis. Its carbohydrate content represents an average of 8.5% of its MW. Glutamic and aspartic acids represent 24% of total amino acids. This protein is called Uronic-Acid-rich Protein (UAP) because of its uronic acid content. The same protein isolated from the urine of stone formers showed less inhibitory activity than that purified from the urine of healthy subjects. Structural modifications may explain this diminution of its inhibitory activity. This protein was also purified from rat urine using same procedures. Human and rat UAP exhibit similar biochemical characteristics and strongly inhibit calcium oxalate crystallization in vitro. Partial amino acid sequence analysis showed a homology with inter-alpha-trypsin inhibitor (ITI), confirmed by the immunological results on Western blot. Nevertheless, various chemical and enzymic treatments revealed that UAP and ITI are not identical molecules. Consequently, urine contains several macromolecular substances belonging to ITI superfamily which are involved in the inhibition of calcium oxalate crystallization. UAP takes place among the most efficient macromolecular substances known as inhibitors in calcium oxalate nephrolithiasis.
在大约十年的时间里,肾钙蛋白被认为是草酸钙晶体生长的主要抑制剂。如今,它似乎只是众多尿蛋白抑制剂中的一种,其他的还有非聚合的Tamm-Horsfall蛋白、尿桥蛋白或晶体基质蛋白(CMP,一种源自凝血酶原的蛋白)。所有这些分子都能够抑制尿液中草酸钙的晶体生长或聚集。另一种名为肾石素的蛋白也被报道是碳酸钙晶体二次成核和生长的有效抑制剂。通过色谱方法从健康受试者的尿液中分离出一种新的草酸钙形成的尿抑制剂。通过聚丙烯酰胺凝胶电泳估计,它是一种分子量(MW)约为35 kDa的大分子。其碳水化合物含量平均占其分子量的8.5%。谷氨酸和天冬氨酸占总氨基酸的24%。由于其富含糖醛酸,这种蛋白被称为富含糖醛酸蛋白(UAP)。从结石形成者尿液中分离出的相同蛋白显示出的抑制活性比从健康受试者尿液中纯化出的蛋白要低。结构修饰可能解释了其抑制活性的降低。同样使用相同程序从大鼠尿液中纯化出了这种蛋白。人和大鼠的UAP表现出相似的生化特性,并在体外强烈抑制草酸钙结晶。部分氨基酸序列分析显示与α-胰蛋白酶抑制剂(ITI)有同源性,蛋白质印迹的免疫结果证实了这一点。然而,各种化学和酶处理表明UAP和ITI并非相同分子。因此,尿液中含有几种属于ITI超家族的大分子物质,它们参与抑制草酸钙结晶。UAP是已知的草酸钙肾结石抑制剂中最有效的大分子物质之一。